PIK3CA and cancer: Indeed, numerous clinical trials have evaluated the efficacy of over 30 drugs targeting different steps of the PI3K/AKT pathway in breast and other cancers, including several AKT inhibitors (AKTis) such as MK2206, AZD5363, and GSK690693.